Saturday, 21 April 2018 - 16:14
  • it
  • de
  • en
  • fr

Uncategorized

Advent offers €1.919bn for Sanofi’s Zentiva

Private equity Advent International has announced today in a press release that it is in exclusive talks with Sanofi to acquire Zentiva, the French company’s arm that markets generics all over Europe. Advent has offered Sanofi €1.919bn. Advent International, which…

Good Phase III results for Eli Lilly’s Cyramza (liver cancer)

US-based Eli Lilly yesterday announced the results from the Phase III REACH-2 clinical trial, conducted on patients with liver cancer (HCC) treated with Cyramza (ramucirumab) as a second-line treatment. The trial has delivered positive results and investors have soon rewarded…

Leo Pharma sells 10 products to Karo Pharma for €260m

Denmark-based Leo Pharma has announced today it has sold the rights to ten products to its Sweden-based competitor Karo Pharma for €260m. The transaction only includes rights, not production sites or R&D staff. The divested brands include Conotrane®, Fonx®, Condyline®,…

Valeant plunges: capitalization down 11% following Q4 2017 results

Canada-based Valeant has had the worst start today. The group led by CEO Joe Papa announced today, before trading started, its Q4 2017 results, which were below analysts’ and investors’ expectations. The company’s shares soon reacted with a 11% decline…

Gilead wins appeal against Merck & Co. and saves $2.54bn

A judge in the federal court in Delaware has ruled in favor of Gilead in an appeal trial concerning patent issues against Merck & Co.. Specifically, the judge has held invalid Merck & Co.’s patent protecting a hepatitis C treatment,…

Japan-based Shionogi develops powerful drug to treat influenza

Japan-based pharmaceutical group Shionogi has reported that it has developed a therapy eliminating the A and B influenza virus in 24 hours with a single dose–a far better result than Roche’s Tamiflu, which requires two doses and a minimum of…

Tigenix obtains ODD by FDA for Chron’s disease therapy (Cx601)

Leuven, Belgium-based TiGenix today obtained by the FDA an ODD (Orphan Drug Designation) for its Cx601 investigational therapy, developed to treat fistulas in patients with Crohn’s disease. Cx601 is an allogeneic, stem-cells therapy already assessed in two Phase III clinical…

Hikma lowers 2017 guidance and shares fall >5%

Hikma Pharmaceuticals today announced it has lowered its current year guidance, which has immediately resulted in a 5% capitalization loss. The news was announced a week after that US FDA rejected – temporarily – to approve the generic of GSK’s…

Third company approaches Stada

Stada announced on a press release it has received another non-binding offer, without disclosing the potential buyer’s name. The German group added that the new bid is of approximately €58.00 per share, which corresponds to valuing the group at approximately…

Stada makes acquisition in the UK

Germany-based pharmaceutical group Stada will enlarge its product portfolio by acquiring UK-based manufacturer of vitamins and food supplements Natures Aid. Natures Aid is headquartered in Preston (Manchester) and has approximately 60 employees. The company generated a revenue of approximately GBP7.3m…

Akzo not to sell Specialty Chemicals segment

Netherlands-based chemical group AkzoNobel will not sell its Specialty Chemicals business unit, denying sale rumors which have been circulating for a long time now. In so doing, Akzo confirms its strategy to remain a manufacturer of chemicals, but also paints…

Angelini too is targeting Sooft Italia (ophthalmic)

Sooft Italia (OOgroup), a company operating in the ophthalmic business, appears to be on sale and, reportedly, UBS has already been mandated to look for a buyer. Potential bidders include VC Principia, Italy-based pharma group Angelini and Mediolanum Farmaceutici. According…

Rise in antidepressant prescriptions for children

A team at Swansea University analyzed the uncontrolled surge in antidepressant prescriptions for children and teenagers. According to the the Welsh university researchers, prescriptions have increased by almost 30% over the past 10 years and drugs not allowed for use…

Mapei intending to pursue M&A again

The Italian chemical group Maipei, specialized in building products, intends to pursue M&A again, with new acquisitions. The company will soon perform two operations of share capital increase – by €25M and by €27.5m – which will bring the total…

Takeda begins extensive trial for new vaccine against Dengue

Takeda, the major Japanese pharma group, has started an important three-year clinical trial for the vaccine against dengue, including vaccination of 20,000 children in Asia and Latin America. The new vaccine TAK-003, developed by Takeda, will provide an alternative to…